AI detects prostate cancer with same level of accuracy as experienced radiologists

FINDINGS

UCLA researchers have developed a new artificial intelligence system to help radiologists improve their ability to diagnose prostate cancer. The system, called FocalNet, helps identify and predict the aggressiveness of the disease evaluating magnetic resonance imaging, or MRI, scans, and it does so with nearly the same level of accuracy as experienced radiologists. In tests, FocalNet was 80.5 percent accurate in reading MRIs, while radiologists with at least 10 years of experience were 83.9 percent accurate.

BACKGROUND

Radiologists use MRI to detect and assess the aggressiveness of malignant prostate tumors. However, it typically takes practicing on thousands of scans to learn how to accurately determine whether a tumor is cancerous or benign and to accurately estimate the grade of the cancer. In addition, many hospitals do not have the resources to implement the highly specialized training required for detecting cancer from MRIs.

METHOD

FocalNet is an artificial neural network that uses an algorithm that comprises more than a million trainable variables; it was developed by the UCLA researchers. The team trained the system by having it analyze MRI scans of 417 men with prostate cancer; scans were fed into the system so that it could learn to assess and classify tumors in a consistent way and have it compare the results to the actual pathology specimen. Researchers compared the artificial intelligence system's results with readings by UCLA radiologists who had more than 10 years of experience.

IMPACT

The research suggests that an artificial intelligence system could save time and potentially provide diagnostic guidance to less-experienced radiologists.

Source: http://newsroom.ucla.edu/releases/artificial-intelligence-radiologists-detecting-prostate-cancer

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Neoantigen DNA vaccines improve survival and immunity in triple-negative breast cancer patients